Amneal Pharmaceuticals (NASDAQ:AMRX) PT Raised to $8.00

Amneal Pharmaceuticals (NASDAQ:AMRX - Free Report) had its price objective hoisted by The Goldman Sachs Group from $6.25 to $8.00 in a report issued on Monday, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

A number of other equities analysts have also recently commented on the company. Truist Financial reiterated a buy rating and set a $9.00 price target (up previously from $7.00) on shares of Amneal Pharmaceuticals in a report on Monday. Piper Sandler boosted their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an overweight rating in a report on Thursday, March 21st. Barclays boosted their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an overweight rating in a report on Monday, January 29th. Finally, StockNews.com cut Amneal Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of Buy and an average price target of $8.25.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock traded down $0.11 during midday trading on Monday, reaching $6.65. 1,788,120 shares of the company's stock were exchanged, compared to its average volume of 1,571,878. Amneal Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $6.90. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.97 and a current ratio of 1.65. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -11.87 and a beta of 1.33. The stock's 50-day simple moving average is $5.78 and its 200 day simple moving average is $5.32.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Friday, March 1st. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. The business had revenue of $616.98 million during the quarter, compared to analysts' expectations of $630.67 million. On average, analysts expect that Amneal Pharmaceuticals will post 0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Amneal Pharmaceuticals by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company's stock valued at $57,174,000 after acquiring an additional 412,599 shares during the period. Rubric Capital Management LP increased its position in Amneal Pharmaceuticals by 98.8% in the 4th quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company's stock valued at $48,560,000 after acquiring an additional 3,975,500 shares during the period. LSV Asset Management increased its position in Amneal Pharmaceuticals by 10.5% in the 3rd quarter. LSV Asset Management now owns 1,429,300 shares of the company's stock valued at $6,032,000 after acquiring an additional 136,100 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Amneal Pharmaceuticals by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,329,508 shares of the company's stock worth $8,070,000 after buying an additional 26,875 shares during the period. Finally, Teacher Retirement System of Texas increased its position in shares of Amneal Pharmaceuticals by 3.4% during the fourth quarter. Teacher Retirement System of Texas now owns 744,752 shares of the company's stock worth $4,521,000 after buying an additional 24,651 shares during the period. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.